[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Neuronetrix Solutions, LLC dba Cognision\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":73},{"warningLetters":4,"total":72},[5,31,52],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":28,"delivery_method":29,"recipient_title":20,"reference_number":20,"action_taken_date":30,"medical_device_id":20,"response_letter_date":20},300,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-20T05:00:00Z\">02\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkare-solutions-llc-dba-zappy-717991-02202026\">Kare Solutions, LLC dba Zappy \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Kare Solutions, LLC dba Zappy \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7660H Fay Ave, Suite 504\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>La Jolla\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92037\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:customer@zappyhealth.com\"> customer@zappyhealth.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 20, 2026\u003C\u002Fp>\u003Cp>Zappy:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fzappyhealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide, tirzepatide, and liraglutide drug products.\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide, tirzepatide, and liraglutide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The compounded semaglutide, tirzepatide, and liraglutide products displayed on your website identify “Zappy” on the pictured label, suggesting Zappy is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, the representations on your website that Zappy is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>Additionally, the following claims concerning compounded semaglutide, tirzepatide, and liraglutide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Semaglutide (Active Pharmaceutical Ingredient in Wegovy®)See Wegovy FDA Information” [sic]\u003C\u002Fli>\u003Cli>“Liraglutide (Active Pharmaceutical Ingredient in Saxenda®)See Saxenda FDA Information” [sic]\u003C\u002Fli>\u003Cli>“Tirzepatide (Active Pharmaceutical Ingredient in Zepbound®)See Zepbound FDA Information” [sic]\u003C\u002Fli>\u003Cli>“a proven medication”\u003C\u002Fli>\u003Cli>“Clinically studied and shown to deliver powerful results when combined with healthy habits.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide, tirzepatide, and liraglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\u003C\u002Fp>\u003Cp>1) Identifying the entities that produce the compounded products offered on your website;\u003C\u002Fp>\u003Cp>2) Providing a representative sample of labeling for such products; and\u003C\u002Fp>\u003Cp>3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide, tirzepatide, and liraglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nKare Solutions, LLC dba Zappy\n\n7660H Fay Ave, Suite 504\n\nLa Jolla, CA 92037\n\nUnited States\n\ncustomer@zappyhealth.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 20, 2026\nZappy:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fzappyhealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide, tirzepatide, and liraglutide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide, tirzepatide, and liraglutide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe compounded semaglutide, tirzepatide, and liraglutide products displayed on your website identify “Zappy” on the pictured label, suggesting Zappy is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that Zappy is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nAdditionally, the following claims concerning compounded semaglutide, tirzepatide, and liraglutide products appear on your website:\n“Semaglutide (Active Pharmaceutical Ingredient in Wegovy®)See Wegovy FDA Information” [sic]\n“Liraglutide (Active Pharmaceutical Ingredient in Saxenda®)See Saxenda FDA Information” [sic]\n“Tirzepatide (Active Pharmaceutical Ingredient in Zepbound®)See Zepbound FDA Information” [sic]\n“a proven medication”\n“Clinically studied and shown to deliver powerful results when combined with healthy habits.”\nCompounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\nFor the reasons discussed above, your compounded semaglutide, tirzepatide, and liraglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\nYou should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\n1) Identifying the entities that produce the compounded products offered on your website;\n2) Providing a representative sample of labeling for such products; and\n3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________________\n1 The semaglutide, tirzepatide, and liraglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].","Kare Solutions, LLC dba Zappy","kare-solutions-llc-dba-zappy-717991-02202026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkare-solutions-llc-dba-zappy-717991-02202026","2026-10-26T08:09:07.758418+00:00","Warning Letter","Issued","2026-03-03","717991","Drugs","2026-08-19T04:54:41.769+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-02-20",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":20,"letter_url":44,"updated_at":45,"action_type":23,"case_status":24,"posted_date":46,"marcs_cms_no":47,"product_type":27,"closeout_date":20,"issuing_office":37,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":20,"reference_number":20,"action_taken_date":51,"medical_device_id":20,"response_letter_date":20},1869,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-09-12T13:00:00Z\">09\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-11T04:00:00Z\">09\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-vitamins-llc-dba-dr-vitamin-solutions-663127-09112023\">DR Vitamins, LLC dba DR Vitamin Solutions\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jonathan Formby\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DR Vitamins, LLC dba DR Vitamin Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7804 Harwood Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>North Richland Hills\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76180-5901\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@drvitaminsolutions.com\"> info@drvitaminsolutions.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 11, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 663127\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Jonathan Formby:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.drvitaminsolutions.com in July 2023. We have also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins; these websites direct consumers to your website www.drvitaminsolutions.com to purchase your products. The FDA has observed that your website offers “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” for sale in the United States.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Additionally, we reviewed your product listings on your Amazon storefront at https:\u002F\u002Fwww.amazon.com\u002Fstores\u002FDRVitaminSolutions\u002Fpage\u002F07F25A08-22FE-4E3D-8C74-5ACF57D4F83F where you have multiple listings of “Vision Clarity Eye Drops.” Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>Your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003C\u002Fp>\n\n\u003Cp>In addition, the drugs “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drug(s) into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your websites, your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website www.drvitaminsolutions.com, your social media websites, https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins, and Amazon storefront that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On your product webpage for “Vision Clarity Eye Drops”:\u003Cbr>\n• \"Say Goodbye To Dry Eyes and Eye Irritations With Vision Clarity Eye Drops!”\u003Cbr>\n• “[C]ontain heavily researched lubricants to help combat dry eye and other irritations.”\u003Cbr>\n• Under “Dosage &amp; Use”: “For use as a lubricant to prevent further irritation or to relieve dryness of the eye.”\u003Cbr>\n• Customer review: “I used to use Bright Eyes III, but this brand seems to feel better when I put the drops in. I continue to see improvement with my cataracts!”\u003Cbr>\n• Customer review: “Great product it really works, I can tell the difference. I recommend it, Beats having an unnecessary and expensive cataract surgery. My eyes are starting to clear up, almost no fogginess.”\u003Cbr>\n• Customer review: “Just wanted you to know my fantastic results with your eye drops. I have been using them for almost a month now and the floaters in my eyes have disappeared. I feel my cataracts are much improved but I will know at my next vision appointment.”\u003Cbr>\n• Customer review: “My mother wanted me to order Vision Clarity drops for her cataracts. Since I am placing my second order for an additional 6 boxes, I must tell you she is very happy. When I look at her eyes now it is amazing. She says she can see better than she has in years.”\u003C\u002Fp>\n\n\u003Cp>On your product webpage for “Life Extension Brite Eyes III”:\u003Cbr>\n• “The Brite Eyes III formula also contains the antioxidant N-acetyl-carnosine . . . Some experts think that carnosine has potential to support antioxidant activity which resists the presence of cataracts on the lens of the eye.”\u003Cbr>\n• Under “Dosage &amp; Use”: “For those with cataracts, glaucoma and other eye ailments, it is recommended to take 1 drop 4 times a day at various intervals morning, noon, evening and before bed.”\u003C\u002Fp>\n\n\u003Cp>On your product webpage for “Can-C Eye Drops”:\u003Cbr>\n• “By providing compounds like N-Acetyl-Carnosine (NAC), these Can-C Eye Drops are made to serve as your ultimate eye shield. As such, they may help to protect the eyes from damage in the form of free radicals, UV rays, and thereby, even cataracts.”\u003C\u002Fp>\n\n\u003Cp>On your product webpage for “Longevity Science Visual Ocuity”:\u003Cbr>\n• “[E]xpertly crafted to aid in the relief of dry, itchy eyes and other afflictions which might cause discomfort and limited vision.”\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Freview-n-acetyl-carnosine-nac-eye-drops-2019\u002F:\u003Cbr>\n• “While Carnosine itself is a familiar amino acid compound with well-documented antioxidant properties, N-Acetyl-Carnosine (NAC) is a unique form of Carnosine with a very distinct intended usage. Over the past decade and a half, NAC eye drops\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> have become an increasingly popular product for resisting and reversing cataracts in both pets and humans.”\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Fbenefits-n-acetyl-carnosine-drops-nac-eyes-especially-cataracts\u002F:\u003Cbr>\n• “N-Acetyl-Carnosine (NAC) drops can help. Especially with cataracts.”\u003Cbr>\n• “There has been quite a bit of research with NAC, N-Acetyl-Carnosine drops especially for cataracts. Results from one study’s conclusion were very encouraging. ‘Topical NAC shows potential for the treatment and prevention of cataracts.’”\u003Cbr>\n• “References:\u003Cbr>\n&nbsp; &nbsp; o gov. Efficacy of N-acetyl-carnosine in treatment of cataracts.\u003Cbr>\n&nbsp; &nbsp; o Dr. David Williams. Carnosine for Cataracts.”\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Fnac-carnosine-eye-drops-and-eye-health\u002F:\u003Cbr>\n• “Eye drops with N-Acetyl-Carnosine (NAC) can be helpful for eye health. There was a 2-year study was done where one group got the NAC drops and one group did not. The group that had used the drops had improvement while the other group got worse. ‘Tolerability of NAC eye drops was good in almost all patients, with no reports of ocular or systemic adverse effects. Topical NAC shows potential for the treatment and prevention of cataracts.’”\u003Cbr>\n• “These drops have been used for several eye health issues, but the most common use is for cataracts. NAC uses natural ingredients and the body’s main antioxidant glutathione to chip away at the damaged cells of the cataracts. The damaged cells are cleared away and healthy cells can be protected from further damage.”\u003C\u002Fp>\n\n\u003Cp>On your social media websites at https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins:\u003Cbr>\n• February 9, 2019 Twitter post: An image of the “Vision Clarity Eye Drops” with the text, “Carnosine, a cataracts worst nightmare.”\u003Cbr>\n• July 11, 2019 Facebook video post: “Today, I would like to talk to you about our Vision Clarity Eye Drops. These are very popular and the key ingredient in them is N-Acetylcarnosine and they also have a lubricant. People use them for various health issues with their eyes, but the most popular by far is cataracts. We do not make any medical claims nor guarantees on any specific health issue, but we are very thankful that for over 10 years, people have been able to avoid having cataract surgery because they’ve used these drops. We suggest using 1 drop in each eye 4 times a day. It typically takes people on average of about 3 months to see a noticeable difference. And the best results usually take several months.”\u003Cbr>\n• July 14, 2023 Facebook post: “Eye Health Bundle Pack . . . includes Can-C Eye Drops . . . ‘I have used these eye drops for many years. I have the the [sic] beginning of cataracts that have not progressed and my near sightedness has not gotten worse in over two years. I also find the drops are soothing to my eyes. I highly recommend this product.’”\u003C\u002Fp>\n\n\u003Cp>On your Amazon product webpage for “Vision Clarity Eye Drops” at https:\u002F\u002Fwww.amazon.com\u002FCarnosine-Lubricants-Hypromellose-Antioxidant-Lubricating\u002Fdp\u002FB008J6QR8Q, you have an image that resembles an over-the-counter (OTC) drug facts label, and it displays Glycerin 1.0% and N-Acetylcarnosine (NAC) 1.0% as active ingredients. Furthermore, next to the OTC drug facts label, you include the claim, “clinically studied ingredients[:] cataracts[,] dry eyes[, and] floaters.”\u003C\u002Fp>\n\n\u003Cp>Your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products.\u003C\u002Fp>\n\n\u003Cp>“Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are marketed as ophthalmic demulcent (lubricant) drug products and are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application – commonly referred to as “OTC monograph drugs” – may be legally marketed if they meet applicable requirements. In particular, ophthalmic demulcent (lubricant) drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter Monograph M018).\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” do not conform to the conditions of use specified in Monograph M018 because these products are formulated with the active ingredient N-Acetyl-Carnosine (NAC), and labeled with indications to treat or prevent cataracts, neither of which are permitted under the final administrative order. Therefore, these products do not meet the requirements under section 505G.\u003C\u002Fp>\n\n\u003Cp>We note that you list the NAC ingredient as an inactive ingredient or excipient on the label of your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products. However, your firm makes many therapeutic claims for NAC that cause it to be considered an active ingredient.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> For example, your website includes a blog post entitled, “The Benefits of N-Acetyl-Carnosine (NAC) for Your Eyes, Especially for Cataracts.” Many other examples of therapeutic claims related to NAC can be found in the various claims cited in this letter above which make it clear that NAC is intended to furnish pharmacological activity or other direct effect, including in the treatment of cataracts, and is thus an active ingredient. As previously stated, NAC is not a permitted active ingredient in Monograph M018 and treating or preventing cataracts is not a permitted indication in Monograph M018.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Registration and Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 510(j)(1) of the FD&amp;C Act, 21 U.S.C. 360(j)(1), and 21 CFR 207.41, all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA. The drug products “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are not properly listed with FDA.5 Therefore, these drug products are misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your firm markets these ophthalmic products as containing N-acetylcarnosine (NAC).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> You include a direct hyperlink to your “Vision Clarity Eye Drops” product webpage.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330 prior to enactment of the CARES Act. In the case of OTC ophthalmic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Your drug listing for “Vision Clarity Eye Drops” (NDC 71108-001-05) is inactive as of January 31, 2020. To date, FDA has not received an updated submission for the drug product “Vision Clarity Eye Drops” (NDC 71108-001-05).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJonathan Formby\n\nRecipient Title\n\nPresident\n\nDR Vitamins, LLC dba DR Vitamin Solutions\n\n7804 Harwood Rd\n\nNorth Richland Hills, TX 76180-5901\n\nUnited States\n\ninfo@drvitaminsolutions.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nSeptember 11, 2023\n\nRE: 663127\n\nDear Jonathan Formby:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.drvitaminsolutions.com in July 2023. We have also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins; these websites direct consumers to your website www.drvitaminsolutions.com to purchase your products. The FDA has observed that your website offers “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” for sale in the United States.1 Additionally, we reviewed your product listings on your Amazon storefront at https:\u002F\u002Fwww.amazon.com\u002Fstores\u002FDRVitaminSolutions\u002Fpage\u002F07F25A08-22FE-4E3D-8C74-5ACF57D4F83F where you have multiple listings of “Vision Clarity Eye Drops.” Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nYour “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\n\nIn addition, the drugs “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drug(s) into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nUnapproved New Drug Violations\n\nBased on a review of your websites, your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website www.drvitaminsolutions.com, your social media websites, https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins, and Amazon storefront that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nOn your product webpage for “Vision Clarity Eye Drops”:\n\n• \"Say Goodbye To Dry Eyes and Eye Irritations With Vision Clarity Eye Drops!”\n\n• “[C]ontain heavily researched lubricants to help combat dry eye and other irritations.”\n\n• Under “Dosage & Use”: “For use as a lubricant to prevent further irritation or to relieve dryness of the eye.”\n\n• Customer review: “I used to use Bright Eyes III, but this brand seems to feel better when I put the drops in. I continue to see improvement with my cataracts!”\n\n• Customer review: “Great product it really works, I can tell the difference. I recommend it, Beats having an unnecessary and expensive cataract surgery. My eyes are starting to clear up, almost no fogginess.”\n\n• Customer review: “Just wanted you to know my fantastic results with your eye drops. I have been using them for almost a month now and the floaters in my eyes have disappeared. I feel my cataracts are much improved but I will know at my next vision appointment.”\n\n• Customer review: “My mother wanted me to order Vision Clarity drops for her cataracts. Since I am placing my second order for an additional 6 boxes, I must tell you she is very happy. When I look at her eyes now it is amazing. She says she can see better than she has in years.”\n\nOn your product webpage for “Life Extension Brite Eyes III”:\n\n• “The Brite Eyes III formula also contains the antioxidant N-acetyl-carnosine . . . Some experts think that carnosine has potential to support antioxidant activity which resists the presence of cataracts on the lens of the eye.”\n\n• Under “Dosage & Use”: “For those with cataracts, glaucoma and other eye ailments, it is recommended to take 1 drop 4 times a day at various intervals morning, noon, evening and before bed.”\n\nOn your product webpage for “Can-C Eye Drops”:\n\n• “By providing compounds like N-Acetyl-Carnosine (NAC), these Can-C Eye Drops are made to serve as your ultimate eye shield. As such, they may help to protect the eyes from damage in the form of free radicals, UV rays, and thereby, even cataracts.”\n\nOn your product webpage for “Longevity Science Visual Ocuity”:\n\n• “[E]xpertly crafted to aid in the relief of dry, itchy eyes and other afflictions which might cause discomfort and limited vision.”\n\nOn your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Freview-n-acetyl-carnosine-nac-eye-drops-2019\u002F:\n\n• “While Carnosine itself is a familiar amino acid compound with well-documented antioxidant properties, N-Acetyl-Carnosine (NAC) is a unique form of Carnosine with a very distinct intended usage. Over the past decade and a half, NAC eye drops2 have become an increasingly popular product for resisting and reversing cataracts in both pets and humans.”\n\nOn your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Fbenefits-n-acetyl-carnosine-drops-nac-eyes-especially-cataracts\u002F:\n\n• “N-Acetyl-Carnosine (NAC) drops can help. Especially with cataracts.”\n\n• “There has been quite a bit of research with NAC, N-Acetyl-Carnosine drops especially for cataracts. Results from one study’s conclusion were very encouraging. ‘Topical NAC shows potential for the treatment and prevention of cataracts.’”\n\n• “References:\n\no gov. Efficacy of N-acetyl-carnosine in treatment of cataracts.\n\no Dr. David Williams. Carnosine for Cataracts.”\n\nOn your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Fnac-carnosine-eye-drops-and-eye-health\u002F:\n\n• “Eye drops with N-Acetyl-Carnosine (NAC) can be helpful for eye health. There was a 2-year study was done where one group got the NAC drops and one group did not. The group that had used the drops had improvement while the other group got worse. ‘Tolerability of NAC eye drops was good in almost all patients, with no reports of ocular or systemic adverse effects. Topical NAC shows potential for the treatment and prevention of cataracts.’”\n\n• “These drops have been used for several eye health issues, but the most common use is for cataracts. NAC uses natural ingredients and the body’s main antioxidant glutathione to chip away at the damaged cells of the cataracts. The damaged cells are cleared away and healthy cells can be protected from further damage.”\n\nOn your social media websites at https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins:\n\n• February 9, 2019 Twitter post: An image of the “Vision Clarity Eye Drops” with the text, “Carnosine, a cataracts worst nightmare.”\n\n• July 11, 2019 Facebook video post: “Today, I would like to talk to you about our Vision Clarity Eye Drops. These are very popular and the key ingredient in them is N-Acetylcarnosine and they also have a lubricant. People use them for various health issues with their eyes, but the most popular by far is cataracts. We do not make any medical claims nor guarantees on any specific health issue, but we are very thankful that for over 10 years, people have been able to avoid having cataract surgery because they’ve used these drops. We suggest using 1 drop in each eye 4 times a day. It typically takes people on average of about 3 months to see a noticeable difference. And the best results usually take several months.”\n\n• July 14, 2023 Facebook post: “Eye Health Bundle Pack . . . includes Can-C Eye Drops . . . ‘I have used these eye drops for many years. I have the the [sic] beginning of cataracts that have not progressed and my near sightedness has not gotten worse in over two years. I also find the drops are soothing to my eyes. I highly recommend this product.’”\n\nOn your Amazon product webpage for “Vision Clarity Eye Drops” at https:\u002F\u002Fwww.amazon.com\u002FCarnosine-Lubricants-Hypromellose-Antioxidant-Lubricating\u002Fdp\u002FB008J6QR8Q, you have an image that resembles an over-the-counter (OTC) drug facts label, and it displays Glycerin 1.0% and N-Acetylcarnosine (NAC) 1.0% as active ingredients. Furthermore, next to the OTC drug facts label, you include the claim, “clinically studied ingredients[:] cataracts[,] dry eyes[, and] floaters.”\n\nYour “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products.\n\n“Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are marketed as ophthalmic demulcent (lubricant) drug products and are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application – commonly referred to as “OTC monograph drugs” – may be legally marketed if they meet applicable requirements. In particular, ophthalmic demulcent (lubricant) drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter Monograph M018).3 However, your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” do not conform to the conditions of use specified in Monograph M018 because these products are formulated with the active ingredient N-Acetyl-Carnosine (NAC), and labeled with indications to treat or prevent cataracts, neither of which are permitted under the final administrative order. Therefore, these products do not meet the requirements under section 505G.\n\nWe note that you list the NAC ingredient as an inactive ingredient or excipient on the label of your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products. However, your firm makes many therapeutic claims for NAC that cause it to be considered an active ingredient.4 For example, your website includes a blog post entitled, “The Benefits of N-Acetyl-Carnosine (NAC) for Your Eyes, Especially for Cataracts.” Many other examples of therapeutic claims related to NAC can be found in the various claims cited in this letter above which make it clear that NAC is intended to furnish pharmacological activity or other direct effect, including in the treatment of cataracts, and is thus an active ingredient. As previously stated, NAC is not a permitted active ingredient in Monograph M018 and treating or preventing cataracts is not a permitted indication in Monograph M018.\n\nFDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nRegistration and Drug Listing Violations\n\nUnder section 510(j)(1) of the FD&C Act, 21 U.S.C. 360(j)(1), and 21 CFR 207.41, all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA. The drug products “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are not properly listed with FDA.5 Therefore, these drug products are misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_______________________\n\n1 Your firm markets these ophthalmic products as containing N-acetylcarnosine (NAC).\n\n2 You include a direct hyperlink to your “Vision Clarity Eye Drops” product webpage.\n\n3 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330 prior to enactment of the CARES Act. In the case of OTC ophthalmic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.)\n\n4 See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.”\n\n5 Your drug listing for “Vision Clarity Eye Drops” (NDC 71108-001-05) is inactive as of January 31, 2020. To date, FDA has not received an updated submission for the drug product “Vision Clarity Eye Drops” (NDC 71108-001-05).","DR Vitamins, LLC dba DR Vitamin Solutions","dr-vitamins-llc-dba-dr-vitamin-solutions-663127-09112023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-vitamins-llc-dba-dr-vitamin-solutions-663127-09112023","2026-10-26T08:08:27.096198+00:00","2023-09-12","663127","Jonathan Formby","2026-08-20T00:41:55.52+00:00","Via Email","2023-09-11",{"id":53,"raw":54,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":20,"letter_url":65,"updated_at":66,"action_type":23,"case_status":24,"posted_date":67,"marcs_cms_no":68,"product_type":69,"closeout_date":20,"issuing_office":58,"recipient_name":20,"body_fetched_at":70,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":71,"medical_device_id":20,"response_letter_date":20},3127,[55,56,57,58,59,13,13,13],"\u003Ctime datetime=\"2021-10-05T13:20:00Z\">10\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-09T04:00:00Z\">08\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpairon-solutions-llc-616392-08092021\">Pairon Solutions LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Pairon Solutions LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13970 SW 72nd Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Portland\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97223\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:melissa@paironsolutions.com\"> melissa@paironsolutions.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>DATE: August 9, 2021\u003Cbr>\n\u003Cbr>\nRe: “Arun KN95 Folding Face Mask,” “Deming Surgical Mask,” and “Pairon 3Ply Face Mask” (Blue, White &amp; Black)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.paironsolutionsppe.com\u002F on July 14, 2021. The FDA has observed that your website offers the “Arun KN95 Folding Face Mask,” the “Deming Surgical Mask”, and the “Pairon 3Ply Face Mask” (Blue, White &amp; Black) for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the Arun KN95 Folding Face Mask, Deming Surgical Mask, and Pairon 3Ply Face Mask (Blue, White &amp; Black) are intended for the mitigation, prevention, treatment, diagnosis, or cure of disease, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Statements made alongside an image of the Arun KN95 Folding Face Mask that it is “listed on FDA EUA for Non-NIOSH Devices” and representing compliance with “GB2626-2006” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Statements alongside an image of the Deming Surgical Mask that it provides “99% bacterial efficiency” and “complies ASTM F2100”. The name also incorporates the word “surgical” as well as “medical” written on the box packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Statements made on the packaging and alongside the images of the Pairon 3Ply Face Mask (Blue, White &amp; Black) that they provide “&gt;95% bacterial efficiency” and “helps filter out … bacteria” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-facemask], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\u003C\u002Fli>\n\t\u003Cli>Statements on your firm’s customer blog page representing that the BLUE – Pairon 3Ply Face Mask has been supplied to nursing home facilities [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fblogs\u002Fnews]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Based on our review, your website is offering for sale in the United States, the Arun KN95 Folding Face Mask (which your website represents is manufactured by Dongguan Arun Industrial Co. Ltd.), the Deming Surgical Mask (which your website represents is manufactured by Xiantao Deming Healthcare Products Co., Ltd.), and the Pairon 3Ply Face Mask - Blue, White &amp; Black (which your website represents is manufactured by Wuxi Hingdou Sports Co., Ltd) without marketing approval or clearance from the FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>In addition, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\u003C\u002Fp>\n\n\u003Cp>Your website contains a number of false or misleading representations, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Representations that the Arun KN95 Folding Face Masks are “Certified: … FDA” and unauthorized display of what appears to be FDA’s logo\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on inner packaging of the product [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Representations that the Deming Surgical Masks are “Certified: FDA” and unauthorized display of what appears to be FDA’s logo on packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Representations that Pairon 3Ply Face Masks (Blue, White &amp; Black) are “FDA Registered” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask] [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black][https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\u003C\u002Fli>\n\t\u003Cli>Unauthorized display of what appears to be FDA’s logo alongside the BLACK – Pairon&nbsp;3Ply Face Mask [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3plyface-mask-black]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certificate of FDA Registration” issued by “UCL-REGSERVICE INC” (UCL-REGSERVICE Certificate) alongside Arun KN95 Folding Face Mask product information. The UCL-REGSERVICE Certificate “certifies that Dongguan Arun Industrial Co. Ltd., …has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” The UCL-REGSERVICE Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certification of Registration” issued by “Sungo Technical Services Inc.” (Sungo Technical Certificate) alongside Deming Surgical Mask product information. The Sungo Technical Certificate “certifies that Xiantao Deming Healthcare Products Co., Ltd., … has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” The Sungo Technical Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certification of Registration” issued by “Wayborn Quality &amp; Technology Services” (Wayborn Certificate) alongside the BLUE – Pairon 3Ply Face Mask product information. The Wayborn Certificate “certifies that … Wuxi Hingdou Sports Co., Ltd., …has completed U.S. FOOD And DRUG Administration Medical Device Registration…” The Wayborn Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>To date, FDA has not cleared, approved, authorized or “Certified” the Arun KN95 Folding Face Mask or the Deming Surgical Mask offered for sale by your firm, and so statements to the contrary are false. In addition, display of the FDA logo on packaging and near images of and information about the Arun KN95 Folding Face Mask, the Deming Surgical Mask, and the Pairon 3Ply Face Mask (Blue, White &amp; Black), combined with statements such as, “Certified: FDA” and “FDA Registered”, are misleading because it creates the impression of official FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the devices and\u002For your establishment.. The UCL-REGSERVICE Certificate bearing the FDA logo, positioned near images of and information about the Arun KN95 Folding Face Mask is misleading because it implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Dongguan Arun Industrial, Co., Ltd. is or was registered with FDA and that the firm is or was in possession of a registration number. In addition, the display of Sungo Technical Certificate bearing the FDA logo positioned near images of and information about the Deming Surgical Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Xiantao Deming Healthcare Products Co., Ltd. registration and possession of a registration number. Furthermore, display of the Wayborn Certificate bearing the FDA logo, near information about the BLUE – Pairon 3Ply Face Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Wuxi Hingdou Sports Co., Ltd registration and possession of a registration number. Although the Arun KN95 Folding Face Mask, Deming Surgical Mask, and BLUE – Pairon 3Ply Face Mask Certificates contain legible language that appears to be intended to function as a disclaimer, including a statement that the Certificates do not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificates. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>We remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration &amp; Device Listing Database merely denotes that the establishment has provided certain information to FDA.\u003C\u002Fp>\n\n\u003Cp>This letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the Document number CMS Case# 616392 or CTS Number CPT2001233 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donna Engleman, MS, BSN\u003Cbr>\nDirector\u003Cbr>\nDivision of Market Intelligence\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Yabo Zhang\u003Cbr>\nDongguan Arun Industrial, Co., Ltd.\u003Cbr>\nNO.18Xingfeng St, Changlong, Huangjiang\u003Cbr>\nDongguan, CN 523766\u003C\u002Fp>\n\n\u003Cp>US Agent:\u003Cbr>\nSimcal\u003Cbr>\nUCL-REG SERVICE INC.\u003Cbr>\n3907 Prince Street Suite 6F\u003Cbr>\nFlushing, NY 11354\u003Cbr>\nEmail: gbstandard@163.com\u003C\u002Fp>\n\n\u003Cp>UCL-Reg Service\u003Cbr>\n602 ROCKWOOD ROAD, WILMINGTON\u003Cbr>\nNew Castle, DE, 19802\u003C\u002Fp>\n\n\u003Cp>XIANTAO DEMING HEALTHCARE PRODUCTS CO., LTD.\u003Cbr>\nNo.198, Pengchang Ave. Pengchang Town, Xiantao City\u003Cbr>\nHubei Province, P.R. China\u003Cbr>\nXiantao, CN 433018\u003C\u002Fp>\n\n\u003Cp>Leeyeo Kee\u003Cbr>\nRegrek LLC\u003Cbr>\n19 Holly Cove Ln.\u003Cbr>\nDover, DE 19901\u003Cbr>\nEmail: regrek.cs@hotmail.com\u003C\u002Fp>\n\n\u003Cp>Sungo Technical Services Inc.\u003Cbr>\n6050 W Eastwood Ave Apt. 201 Chicago Illinois 60630\u003Cbr>\nE-mail：sungo.group@yahoo.com\u003Cbr>\nEmail: Shage2008@126.com\u003C\u002Fp>\n\n\u003Cp>WUXI HINGDOU SPORTS CO., LTD\u003Cbr>\nHongdou Industrial Park, Donggang Town\u003Cbr>\nWuxi, Jiangsu, 214000, China\u003C\u002Fp>\n\n\u003Cp>Director: Crane Yu\u003Cbr>\nWayborn Quality &amp; Technology Services\u003Cbr>\n306, Xincheng International Main Building,\u003Cbr>\nNo.535 Qingshuiqiao Road, Ningbo High-tech Zone\u003Cbr>\nEmail: wayborn@wayb.org\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>)\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nPairon Solutions LLC\n\n13970 SW 72nd Ave\n\nPortland, OR 97223\n\nUnited States\n\nmelissa@paironsolutions.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDATE: August 9, 2021\n\nRe: “Arun KN95 Folding Face Mask,” “Deming Surgical Mask,” and “Pairon 3Ply Face Mask” (Blue, White & Black)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.paironsolutionsppe.com\u002F on July 14, 2021. The FDA has observed that your website offers the “Arun KN95 Folding Face Mask,” the “Deming Surgical Mask”, and the “Pairon 3Ply Face Mask” (Blue, White & Black) for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the Arun KN95 Folding Face Mask, Deming Surgical Mask, and Pairon 3Ply Face Mask (Blue, White & Black) are intended for the mitigation, prevention, treatment, diagnosis, or cure of disease, including but not limited to:\n\nStatements made alongside an image of the Arun KN95 Folding Face Mask that it is “listed on FDA EUA for Non-NIOSH Devices” and representing compliance with “GB2626-2006” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nStatements alongside an image of the Deming Surgical Mask that it provides “99% bacterial efficiency” and “complies ASTM F2100”. The name also incorporates the word “surgical” as well as “medical” written on the box packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nStatements made on the packaging and alongside the images of the Pairon 3Ply Face Mask (Blue, White & Black) that they provide “>95% bacterial efficiency” and “helps filter out … bacteria” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-facemask], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\n\nStatements on your firm’s customer blog page representing that the BLUE – Pairon 3Ply Face Mask has been supplied to nursing home facilities [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fblogs\u002Fnews]\n\nBased on our review, your website is offering for sale in the United States, the Arun KN95 Folding Face Mask (which your website represents is manufactured by Dongguan Arun Industrial Co. Ltd.), the Deming Surgical Mask (which your website represents is manufactured by Xiantao Deming Healthcare Products Co., Ltd.), and the Pairon 3Ply Face Mask - Blue, White & Black (which your website represents is manufactured by Wuxi Hingdou Sports Co., Ltd) without marketing approval or clearance from the FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nIn addition, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\n\nYour website contains a number of false or misleading representations, including but not limited to:\n\nRepresentations that the Arun KN95 Folding Face Masks are “Certified: … FDA” and unauthorized display of what appears to be FDA’s logo1 on inner packaging of the product [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nRepresentations that the Deming Surgical Masks are “Certified: FDA” and unauthorized display of what appears to be FDA’s logo on packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nRepresentations that Pairon 3Ply Face Masks (Blue, White & Black) are “FDA Registered” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask] [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black][https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\n\nUnauthorized display of what appears to be FDA’s logo alongside the BLACK – Pairon 3Ply Face Mask [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3plyface-mask-black]\n\nDisplaying a “Certificate of FDA Registration” issued by “UCL-REGSERVICE INC” (UCL-REGSERVICE Certificate) alongside Arun KN95 Folding Face Mask product information. The UCL-REGSERVICE Certificate “certifies that Dongguan Arun Industrial Co. Ltd., …has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” The UCL-REGSERVICE Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo1 and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nDisplaying a “Certification of Registration” issued by “Sungo Technical Services Inc.” (Sungo Technical Certificate) alongside Deming Surgical Mask product information. The Sungo Technical Certificate “certifies that Xiantao Deming Healthcare Products Co., Ltd., … has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” The Sungo Technical Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nDisplaying a “Certification of Registration” issued by “Wayborn Quality & Technology Services” (Wayborn Certificate) alongside the BLUE – Pairon 3Ply Face Mask product information. The Wayborn Certificate “certifies that … Wuxi Hingdou Sports Co., Ltd., …has completed U.S. FOOD And DRUG Administration Medical Device Registration…” The Wayborn Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask]\n\nTo date, FDA has not cleared, approved, authorized or “Certified” the Arun KN95 Folding Face Mask or the Deming Surgical Mask offered for sale by your firm, and so statements to the contrary are false. In addition, display of the FDA logo on packaging and near images of and information about the Arun KN95 Folding Face Mask, the Deming Surgical Mask, and the Pairon 3Ply Face Mask (Blue, White & Black), combined with statements such as, “Certified: FDA” and “FDA Registered”, are misleading because it creates the impression of official FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the devices and\u002For your establishment.. The UCL-REGSERVICE Certificate bearing the FDA logo, positioned near images of and information about the Arun KN95 Folding Face Mask is misleading because it implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Dongguan Arun Industrial, Co., Ltd. is or was registered with FDA and that the firm is or was in possession of a registration number. In addition, the display of Sungo Technical Certificate bearing the FDA logo positioned near images of and information about the Deming Surgical Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Xiantao Deming Healthcare Products Co., Ltd. registration and possession of a registration number. Furthermore, display of the Wayborn Certificate bearing the FDA logo, near information about the BLUE – Pairon 3Ply Face Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Wuxi Hingdou Sports Co., Ltd registration and possession of a registration number. Although the Arun KN95 Folding Face Mask, Deming Surgical Mask, and BLUE – Pairon 3Ply Face Mask Certificates contain legible language that appears to be intended to function as a disclaimer, including a statement that the Certificates do not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificates. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nWe remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration & Device Listing Database merely denotes that the establishment has provided certain information to FDA.\n\nThis letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the Document number CMS Case# 616392 or CTS Number CPT2001233 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonna Engleman, MS, BSN\n\nDirector\n\nDivision of Market Intelligence\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nYabo Zhang\n\nDongguan Arun Industrial, Co., Ltd.\n\nNO.18Xingfeng St, Changlong, Huangjiang\n\nDongguan, CN 523766\n\nUS Agent:\n\nSimcal\n\nUCL-REG SERVICE INC.\n\n3907 Prince Street Suite 6F\n\nFlushing, NY 11354\n\nEmail: gbstandard@163.com\n\nUCL-Reg Service\n\n602 ROCKWOOD ROAD, WILMINGTON\n\nNew Castle, DE, 19802\n\nXIANTAO DEMING HEALTHCARE PRODUCTS CO., LTD.\n\nNo.198, Pengchang Ave. Pengchang Town, Xiantao City\n\nHubei Province, P.R. China\n\nXiantao, CN 433018\n\nLeeyeo Kee\n\nRegrek LLC\n\n19 Holly Cove Ln.\n\nDover, DE 19901\n\nEmail: regrek.cs@hotmail.com\n\nSungo Technical Services Inc.\n\n6050 W Eastwood Ave Apt. 201 Chicago Illinois 60630\n\nE-mail：sungo.group@yahoo.com\n\nEmail: Shage2008@126.com\n\nWUXI HINGDOU SPORTS CO., LTD\n\nHongdou Industrial Park, Donggang Town\n\nWuxi, Jiangsu, 214000, China\n\nDirector: Crane Yu\n\nWayborn Quality & Technology Services\n\n306, Xincheng International Main Building,\n\nNo.535 Qingshuiqiao Road, Ningbo High-tech Zone\n\nEmail: wayborn@wayb.org\n\n___________________________\n\n1 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy)","Pairon Solutions LLC","pairon-solutions-llc-616392-08092021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpairon-solutions-llc-616392-08092021","2026-10-26T08:09:39.952179+00:00","2021-10-05","616392","Medical Devices","2026-08-20T02:35:05.169+00:00","2021-08-09",3,{"510k":74,"classification":75,"enforcement":76,"event":77,"event_backfill":78,"pma":79,"warning_letter":80},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]